Dr. Kamdar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2190 E 11th Avenue
2190 E 11th Avenue
Denver, CO 80206Phone+1 252-847-4268
Education & Training
- Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
- ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2007 - 2010
- KJ Somaiya Medical CollegeClass of 2004
Certifications & Licensure
- CA State Medical License 2013 - Present
- CO State Medical License 2014 - 2025
- WY State Medical License 2021 - 2025
- NC State Medical License 2007 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Start of enrollment: 2020 Nov 23
- POLA+BR for Relapsed or Refractory DLBCL Start of enrollment: 2021 Jan 29
Publications & Presentations
PubMed
- 97 citationsEfficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatme...Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel
Leukemia. 2022-04-01 - 8 citationsHealth-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu
Blood Advances. 2022-12-13 - 110 citationsLisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Blood. 2023-04-06
Abstracts/Posters
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin LymphomaManali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized StudyManali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Sin...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- School of Medicine Honors Distinguished CliniciansMarch 29th, 2023
- Why Is CAR T-cell Therapy ‘One of the Most Phenomenal Advances in Science’?August 16th, 2022
- CAR T-cell Therapy Transforming Science and Cancer Patient Outcomes at CU AnschutzAugust 15th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: